LXEO
Price
$3.14Alerts
Change
+$0.08 (+2.61%)
Updated
Nov 11, 03:20 PM (EDT)
Capitalization
237.23M
Earnings call today
Intraday BUY SELL Signals
NUVB
Price
$4.34Alerts
Change
+$0.14 (+3.33%)
Updated
Nov 11, 03:25 PM (EDT)
Capitalization
1.46B
120 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

LXEO vs NUVB

LXEO vs NUVB Comparison Chart in %
View a ticker or compare two or three
VS
LXEO vs. NUVB commentary
Nov 11, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXEO is a Hold and NUVB is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for LXEO with price predictions
Nov 10, 2026

LXEO in +5.56% Uptrend, rising for three consecutive days on November 04, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where LXEO advanced for three days, in 152 of 180 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where LXEO's RSI Indicator exited the oversold zone, 12 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LXEO as a result. In 40 of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 83%.

The Moving Average Convergence Divergence (MACD) for LXEO just turned positive on October 20, 2026. Looking at past instances where LXEO's MACD turned positive, the stock continued to rise in 25 of 31 cases over the following month. The odds of a continued upward trend are 81%.

LXEO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 30 of 37 cases where LXEO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 81%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LXEO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for LXEO entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.009) is normal, around the industry mean (3.498). P/E Ratio (-3.284) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. LXEO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LXEO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for NUVB with price predictions
Nov 10, 2026

NUVB's RSI Indicator ascends from oversold territory

The RSI Oscillator for NUVB moved out of oversold territory on November 09, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 30 similar instances when the indicator left oversold territory. In 30 of the 30 cases the stock moved higher. This puts the odds of a move higher at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for NUVB just turned positive on October 21, 2026. Looking at past instances where NUVB's MACD turned positive, the stock continued to rise in 43 of 52 cases over the following month. The odds of a continued upward trend are 83%.

Following a +3.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where NUVB advanced for three days, in 204 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.

NUVB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NUVB as a result. In 80 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 89%.

The 50-day moving average for NUVB moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NUVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.

The Aroon Indicator for NUVB entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.754) is normal, around the industry mean (3.498). P/E Ratio (-9.455) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (11.765) is also within normal values, averaging (440.869).

The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. NUVB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NUVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
NUVB: Fundamental Ratings
NUVB
OUTLOOK RATING
1..100
23
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
73
P/E GROWTH RATING
1..100
13
SEASONALITY SCORE
1..100
75

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
LXEONUVB
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
81%
Bullish Trend 2 days ago
82%
Momentum
ODDS (%)
Bullish Trend 2 days ago
83%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 8 days ago
84%
Bullish Trend 8 days ago
84%
Declines
ODDS (%)
Bearish Trend 6 days ago
90%
Bearish Trend 6 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
88%
Aroon
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 11, 2026
Stock price -- (LXEO: $3.06 vs. NUVB: $4.20)
Brand notoriety: LXEO and NUVB are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXEO: 56% vs. NUVB: 65%
Market capitalization -- LXEO: $237.23M vs. NUVB: $1.46B
LXEO [@Biotechnology] is valued at $237.23M. NUVB’s [@Biotechnology] market capitalization is $1.46B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXEO’s FA Score shows that 1 FA rating(s) are green while NUVB’s FA Score has 2 green FA rating(s).

  • LXEO’s FA Score: 1 green, 4 red.
  • NUVB’s FA Score: 2 green, 3 red.
According to our system of comparison, NUVB is a better buy in the long-term than LXEO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXEO’s TA Score shows that 5 TA indicator(s) are bullish while NUVB’s TA Score has 5 bullish TA indicator(s).

  • LXEO’s TA Score: 5 bullish, 3 bearish.
  • NUVB’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LXEO is a better buy in the short-term than NUVB.

Price Growth

LXEO (@Biotechnology) experienced а -1.61% price change this week, while NUVB (@Biotechnology) price change was -10.45% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.

Reported Earning Dates

LXEO is expected to report earnings on Nov 11, 2026.

NUVB is expected to report earnings on Mar 11, 2027.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

LXEO and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXEO has been loosely correlated with SLDB. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if LXEO jumps, then SLDB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXEO
1D Price
Change %
LXEO100%
-2.55%
SLDB - LXEO
52%
Loosely correlated
+2.14%
EDIT - LXEO
51%
Loosely correlated
-8.91%
PRME - LXEO
51%
Loosely correlated
-9.30%
IMVT - LXEO
51%
Loosely correlated
+1.59%
IMNM - LXEO
51%
Loosely correlated
-3.67%
More

NUVB and

Correlation & Price change

A.I.dvisor indicates that over the last year, NUVB has been loosely correlated with SVRA. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if NUVB jumps, then SVRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NUVB
1D Price
Change %
NUVB100%
-3.45%
SVRA - NUVB
44%
Loosely correlated
-2.57%
LXEO - NUVB
44%
Loosely correlated
-2.55%
FDMT - NUVB
41%
Loosely correlated
-0.16%
VCYT - NUVB
40%
Loosely correlated
-7.18%
KYTX - NUVB
39%
Loosely correlated
-1.74%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HAPS38.44N/A
N/A
Harbor Human Capital Factor US Small Cap ETF (HAPS)
FFIU21.03-0.05
-0.26%
UVA Unconstrained Medium-Term Fixed Income ETF (FFIU)
DXJ57.89-0.19
-0.33%
WisdomTree Japan Hedged Equity Fund (DXJ)
DADS18.01-0.09
-0.50%
Digital Asset Debt Strategy ETF (DADS)
YLD18.20-0.11
-0.60%
Principal Active High Yield ETF (YLD)